WCLC 2025 - Posters & ePosters-P1.11.23 Co-Culturing LCOs and Lymphocytes Derived From Pleural Effusion Potentially Implement Personalized Immunotherapy

P1.11.23 Co-Culturing LCOs and Lymphocytes Derived From Pleural Effusion Potentially Implement Personalized Immunotherapy

Back to course

Pdf Summary

This study presents the development of a co-culture system combining lung cancer organoids and lymphocytes derived from malignant pleural effusion, aiming to enable personalized immunotherapy for lung cancer patients. The researchers isolated lymphocytes from both peripheral blood (PBMC) and malignant pleural effusion (MPEL) to compare their differential responses when co-cultured with patient-derived lung cancer organoids. Pathological validation confirmed the system's biological relevance.<br /><br />The system was used to predict and validate drug sensitivity, assessing both immune-based therapies and targeted treatments. Results suggest the co-culture model effectively mirrors patient-specific tumor-immune interactions and responses, providing a platform to evaluate therapeutic efficacy more precisely than conventional methods.<br /><br />Further analysis identified key factors influencing successful establishment of the organoid-lymphocyte co-culture and demonstrated that drug sensitivity results from this system showed good consistency with actual clinical outcomes. This indicates the potential of the platform to guide individualized treatment plans by predicting patient responses to various therapies.<br /><br />Overall, the study introduces a novel lung cancer model integrating tumor organoids with lymphocytes derived from pleural effusion, offering a promising approach to personalize immunotherapy strategies and improve clinical efficacy in lung cancer management.

Asset Subtitle

Xu-Hui Guan

Meta Tag

Speaker Xu-Hui Guan

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

lung cancer organoids

lymphocytes

malignant pleural effusion

co-culture system

personalized immunotherapy

PBMC

drug sensitivity

tumor-immune interactions

targeted treatments

clinical outcomes